Drug Profile
Venadaparib - Idience
Alternative Names: IDX 1197 HCl; IDX-1197; NOV1401 - National OncoVenture; NOV140101Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ildong Pharmaceutical
- Developer Idience
- Class Antineoplastics; Azetidines; Phthalazines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Gastric cancer
Most Recent Events
- 18 Jan 2024 Efficacy data from phase-I/II in gastric cancer presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2024 (ASCO-GCS-2024)
- 05 Aug 2022 Venadaparib - Idience receives Orphan Drug status for Gastric cancer in USA
- 23 Jul 2022 Idience completes a phase-I trial (In Volunteers) in South Korea (PO) (NCT05202912)